AIM ImmunoTech Inc. — Director's Dealing 2019

Aug 2, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-07-31

Reporting Person: MITCHELL WILLIAM M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-07-31	Common Stock	J	1618	$2.35	Acquired	24620	Direct

Footnotes

F1: Shares issued for 50 percent of Director's fee for the second half of July, 2019.